source
- Yarrow goes public while Otsuka receives FDA approval for new ADHD medicationYarrow Bioscience completed a merger that took the company public and will now trade under its own ticker. The firm is developing an anti-TSHR antibody aimed at treating Graves’ disease and the ass…
- RA Capital backs Oak Hill Bio's Nasdaq debut via $175 million SPAC mergerRA Capital announced that its SPAC, Research Alliance Corporation III, will merge with Oak Hill Bio, creating a new Nasdaq-listed rare-disease company. The combined entity will start with $175 mil…